Tiapride

DB13025

small molecule investigational

Deskripsi

Tiapride is a selective D2 and D3 dopamine receptor blocker in the brain.

Struktur Molekul 2D

Berat 328.427
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 2.9–3.6 hours
Volume Distribusi Tiapride distributes rapidly and exhibits virtually no binding to plasma proteins, giving it a relatively high volume of distribution
Klirens (Clearance) 16.6 l/h.

Absorpsi

The bioavailability of tiapride is approximately 75 percent. It has a Tmax is 0.4-1.5 hours and Tss is 24-48 hours with 3 time daily dosing. Benzamide and its derivatives are highly water-soluble but known to cross the blood-brain barrier, necessitating carrier-mediated transport.

Metabolisme

Tiapride is minimally metabolized in humans, 70 % of the drug is eliminated in unchanged form in the urine within 24 hours. Only low concentration of N-desethyl tiapride and tiapride N-oxide and no phase II metabolites were detected.

Rute Eliminasi

Urine (70% as unchanged tiapride)

Interaksi Obat

1335 Data
Buprenorphine Tiapride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Hydrocodone Tiapride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Magnesium sulfate The therapeutic efficacy of Tiapride can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Tiapride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Tiapride may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Mirtazapine Tiapride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Orphenadrine Tiapride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Tiapride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Rotigotine Tiapride may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Tiapride.
Sodium oxybate Tiapride may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Tiapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Thalidomide Tiapride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Tiapride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Amisulpride Tiapride may increase the antipsychotic activities of Amisulpride.
Methylphenidate The risk or severity of adverse effects can be increased when Tiapride is combined with Methylphenidate.
Dexmethylphenidate The risk or severity of adverse effects can be increased when Tiapride is combined with Dexmethylphenidate.
Metoclopramide The risk or severity of adverse effects can be increased when Metoclopramide is combined with Tiapride.
Quinagolide The therapeutic efficacy of Quinagolide can be decreased when used in combination with Tiapride.
Sulpiride Tiapride may increase the antipsychotic activities of Sulpiride.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Tiapride.
Lithium hydroxide Lithium hydroxide may increase the neurotoxic activities of Tiapride.
Lithium citrate Lithium citrate may increase the neurotoxic activities of Tiapride.
Mequitazine Tiapride may increase the arrhythmogenic activities of Mequitazine.
Ethanol Tiapride may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Tiapride may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.
Zimelidine The risk or severity of adverse effects can be increased when Tiapride is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Tiapride is combined with Dapoxetine.
Seproxetine The risk or severity of adverse effects can be increased when Tiapride is combined with Seproxetine.
Fluvoxamine The risk or severity of adverse effects can be increased when Tiapride is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Tiapride is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Tiapride is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Tiapride is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Tiapride is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Tiapride is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Tiapride is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Tiapride is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Tiapride is combined with Escitalopram.
Milnacipran The risk or severity of adverse effects can be increased when Tiapride is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Tiapride is combined with Desvenlafaxine.
Levomilnacipran The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Tiapride.
Indalpine The risk or severity of adverse effects can be increased when Tiapride is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Tiapride is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Tiapride is combined with Alaproclate.
Disopyramide Disopyramide may decrease the excretion rate of Tiapride which could result in a higher serum level.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Tiapride.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Tiapride.
Propantheline Propantheline may decrease the excretion rate of Tiapride which could result in a higher serum level.
Dicyclomine Dicyclomine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Tolterodine Tolterodine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Flavoxate Flavoxate may decrease the excretion rate of Tiapride which could result in a higher serum level.
Tiotropium Tiotropium may decrease the excretion rate of Tiapride which could result in a higher serum level.
Fesoterodine Fesoterodine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Aclidinium Aclidinium may decrease the excretion rate of Tiapride which could result in a higher serum level.
Trimebutine Trimebutine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Imidafenacin Imidafenacin may decrease the excretion rate of Tiapride which could result in a higher serum level.
Propiverine Propiverine may decrease the excretion rate of Tiapride which could result in a higher serum level.
Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Tiapride.
Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Tiapride.
Doxepin The risk or severity of adverse effects can be increased when Doxepin is combined with Tiapride.
Desipramine The risk or severity of adverse effects can be increased when Desipramine is combined with Tiapride.
Zopiclone The risk or severity of adverse effects can be increased when Tiapride is combined with Zopiclone.
Eletriptan The risk or severity of adverse effects can be increased when Eletriptan is combined with Tiapride.
Cabergoline The risk or severity of adverse effects can be increased when Cabergoline is combined with Tiapride.
Zolmitriptan The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Tiapride.
Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Tiapride.
Mazindol The risk or severity of adverse effects can be increased when Mazindol is combined with Tiapride.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Tiapride.
Ergotamine The risk or severity of adverse effects can be increased when Ergotamine is combined with Tiapride.
Naratriptan The risk or severity of adverse effects can be increased when Naratriptan is combined with Tiapride.
Frovatriptan The risk or severity of adverse effects can be increased when Frovatriptan is combined with Tiapride.
Chlorpheniramine The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Tiapride.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Tiapride.
Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Tiapride.
Ergometrine The risk or severity of adverse effects can be increased when Ergometrine is combined with Tiapride.
Lorpiprazole The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Tiapride.
Amphetamine Tiapride may decrease the stimulatory activities of Amphetamine.
Phentermine Tiapride may decrease the stimulatory activities of Phentermine.
Pseudoephedrine Tiapride may decrease the stimulatory activities of Pseudoephedrine.
Benzphetamine Tiapride may decrease the stimulatory activities of Benzphetamine.
Diethylpropion Tiapride may decrease the stimulatory activities of Diethylpropion.
Lisdexamfetamine Tiapride may decrease the stimulatory activities of Lisdexamfetamine.
Mephentermine Tiapride may decrease the stimulatory activities of Mephentermine.
MMDA Tiapride may decrease the stimulatory activities of MMDA.
2,5-Dimethoxy-4-ethylamphetamine Tiapride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
Chlorphentermine Tiapride may decrease the stimulatory activities of Chlorphentermine.
Methylenedioxyethamphetamine Tiapride may decrease the stimulatory activities of Methylenedioxyethamphetamine.
Dextroamphetamine Tiapride may decrease the stimulatory activities of Dextroamphetamine.
Metamfetamine Tiapride may decrease the stimulatory activities of Metamfetamine.
Iofetamine I-123 Tiapride may decrease the stimulatory activities of Iofetamine I-123.
Ritobegron Tiapride may decrease the stimulatory activities of Ritobegron.

Target Protein

Sodium channel protein type 10 subunit alpha SCN10A
D(2) dopamine receptor DRD2
D(3) dopamine receptor DRD3
Serotonin Receptors HTR1A
Alpha-1 adrenergic receptors ADRA1A
Alpha-2 adrenergic receptors ADRA2A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 11520476
    Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger DJ, Rouquier L, Porsolt R: The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001 Jan;16 Suppl 1:29s-34s.
  • PMID: 10721880
    Dose M, Lange HW: The benzamide tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry. 2000 Jan;33(1):19-27.
  • PMID: 7201401
    Bischoff S, Bittiger H, Delini-Stula A, Ortmann R: Septo-hippocampal system: target for substituted benzamides. Eur J Pharmacol. 1982 Apr 23;79(3-4):225-32.
  • PMID: 2958291
    Norman T, Chiu E, James RH, Gregory MS: Single oral dose pharmacokinetics of tiapride in patients with Huntington's disease. Eur J Clin Pharmacol. 1987;32(6):583-6.

Contoh Produk & Brand

Produk: 0 • International brands: 5
International Brands
  • Gramalil
  • Italprid
  • Luxoben
  • Sereprile
  • Tiapridal

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul